Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms.


Journal

Science (New York, N.Y.)
ISSN: 1095-9203
Titre abrégé: Science
Pays: United States
ID NLM: 0404511

Informations de publication

Date de publication:
20 11 2020
Historique:
received: 14 08 2020
accepted: 21 09 2020
pubmed: 26 9 2020
medline: 2 12 2020
entrez: 25 9 2020
Statut: ppublish

Résumé

Efficient therapeutic options are needed to control the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that has caused more than 922,000 fatalities as of 13 September 2020. We report the isolation and characterization of two ultrapotent SARS-CoV-2 human neutralizing antibodies (S2E12 and S2M11) that protect hamsters against SARS-CoV-2 challenge. Cryo-electron microscopy structures show that S2E12 and S2M11 competitively block angiotensin-converting enzyme 2 (ACE2) attachment and that S2M11 also locks the spike in a closed conformation by recognition of a quaternary epitope spanning two adjacent receptor-binding domains. Antibody cocktails that include S2M11, S2E12, or the previously identified S309 antibody broadly neutralize a panel of circulating SARS-CoV-2 isolates and activate effector functions. Our results pave the way to implement antibody cocktails for prophylaxis or therapy, circumventing or limiting the emergence of viral escape mutants.

Identifiants

pubmed: 32972994
pii: science.abe3354
doi: 10.1126/science.abe3354
pmc: PMC7857395
doi:

Substances chimiques

Antibodies, Neutralizing 0
Antibodies, Viral 0
Immunodominant Epitopes 0
Spike Glycoprotein, Coronavirus 0
spike protein, SARS-CoV-2 0
Peptidyl-Dipeptidase A EC 3.4.15.1
ACE2 protein, human EC 3.4.17.23
Angiotensin-Converting Enzyme 2 EC 3.4.17.23

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

950-957

Subventions

Organisme : NIAID NIH HHS
ID : HHSN272201700059C
Pays : United States
Organisme : Bill & Melinda Gates Foundation
ID : INV-006366
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM120553
Pays : United States
Organisme : NIH HHS
ID : S10 OD023476
Pays : United States

Informations de copyright

Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Références

Nature. 2020 Aug;584(7819):120-124
pubmed: 32454512
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
Microbiol Spectr. 2016 Dec;4(6):
pubmed: 28087938
Nucleic Acids Res. 2008 Jul 1;36(Web Server issue):W503-8
pubmed: 18503082
Nature. 2020 May;581(7807):221-224
pubmed: 32225175
Nat Struct Mol Biol. 2020 Oct;27(10):942-949
pubmed: 32753755
Nature. 2020 Aug;584(7819):115-119
pubmed: 32454513
Nature. 2020 Aug;584(7821):443-449
pubmed: 32668443
Acta Crystallogr D Struct Biol. 2019 Oct 1;75(Pt 10):861-877
pubmed: 31588918
Proc Natl Acad Sci U S A. 2019 Jan 29;116(5):1591-1596
pubmed: 30642974
Cell. 2020 Sep 3;182(5):1284-1294.e9
pubmed: 32730807
J Struct Biol. 2005 Jul;151(1):41-60
pubmed: 15890530
Cell. 2020 May 14;181(4):894-904.e9
pubmed: 32275855
Science. 2020 Aug 21;369(6506):1010-1014
pubmed: 32540901
Nature. 2020 Dec;588(7838):498-502
pubmed: 32805734
Nature. 2020 Aug;584(7821):437-442
pubmed: 32555388
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
J Immunol. 2020 Aug 15;205(4):915-922
pubmed: 32591393
Elife. 2016 Nov 15;5:
pubmed: 27845625
Proc Natl Acad Sci U S A. 2017 Aug 29;114(35):E7348-E7357
pubmed: 28807998
N Engl J Med. 2003 May 15;348(20):1953-66
pubmed: 12690092
Structure. 2019 Jan 2;27(1):134-139.e3
pubmed: 30344107
Acta Crystallogr D Biol Crystallogr. 2011 Apr;67(Pt 4):355-67
pubmed: 21460454
Lancet. 2020 Aug 15;396(10249):467-478
pubmed: 32702298
Nature. 2020 Jul;583(7815):290-295
pubmed: 32422645
Nat Struct Mol Biol. 2015 Nov;22(11):833-4
pubmed: 26581513
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
N Engl J Med. 2020 Nov 12;383(20):1920-1931
pubmed: 32663912
Nat Methods. 2017 Mar;14(3):290-296
pubmed: 28165473
Elife. 2016 Sep 26;5:
pubmed: 27669148
Antiviral Res. 2016 Apr;128:7-19
pubmed: 26794397
Acta Crystallogr D Biol Crystallogr. 2010 Jan;66(Pt 1):12-21
pubmed: 20057044
Sci Rep. 2017 Dec 7;7(1):17169
pubmed: 29215033
Nature. 2020 Aug;584(7821):450-456
pubmed: 32698192
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
mBio. 2018 Sep 11;9(5):
pubmed: 30206174
Science. 2020 Sep 18;369(6510):1501-1505
pubmed: 32703906
IUCrJ. 2019 Jan 01;6(Pt 1):5-17
pubmed: 30713699
Nat Methods. 2015 Apr;12(4):361-365
pubmed: 25707030
Nat Immunol. 2015 Feb;16(2):170-177
pubmed: 25501631
N Engl J Med. 2003 May 15;348(20):1967-76
pubmed: 12690091
Science. 2020 Aug 21;369(6506):956-963
pubmed: 32540903
Cell Host Microbe. 2020 Sep 9;28(3):475-485.e5
pubmed: 32735849
Nat Microbiol. 2020 Apr;5(4):562-569
pubmed: 32094589
Ultramicroscopy. 2013 Dec;135:24-35
pubmed: 23872039
Science. 2020 Jun 12;368(6496):1274-1278
pubmed: 32404477
Acta Crystallogr D Biol Crystallogr. 2010 Apr;66(Pt 4):486-501
pubmed: 20383002
Adv Virus Res. 2019;105:93-116
pubmed: 31522710
Cell. 2020 Sep 3;182(5):1295-1310.e20
pubmed: 32841599
Immunity. 2018 Apr 17;48(4):799-811.e9
pubmed: 29669253
Lancet. 2020 Jun 13;395(10240):1845-1854
pubmed: 32450106
Nat Commun. 2020 Oct 15;11(1):5214
pubmed: 33060595
Antiviral Res. 1990 Oct-Nov;14(4-5):181-205
pubmed: 2088205
Elife. 2018 Nov 09;7:
pubmed: 30412051
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):125-32
pubmed: 20124692
Science. 2020 Mar 27;367(6485):1444-1448
pubmed: 32132184
Science. 2020 Aug 14;369(6505):806-811
pubmed: 32434945
Nat Commun. 2020 Mar 27;11(1):1620
pubmed: 32221306
Nat Methods. 2020 Dec;17(12):1214-1221
pubmed: 33257830
PLoS Pathog. 2018 Feb 26;14(2):e1006934
pubmed: 29481552
Curr Biol. 2020 Jun 8;30(11):2196-2203.e3
pubmed: 32416074
Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):18950-5
pubmed: 20956322
Science. 2020 Aug 7;369(6504):643-650
pubmed: 32540902
Cell. 2020 Aug 20;182(4):828-842.e16
pubmed: 32645326
J Appl Crystallogr. 2007 Aug 1;40(Pt 4):658-674
pubmed: 19461840
Cell. 2020 Nov 12;183(4):1024-1042.e21
pubmed: 32991844
Nat Methods. 2019 Nov;16(11):1146-1152
pubmed: 31591575
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
PLoS Pathog. 2015 May 29;11(5):e1004932
pubmed: 26023780
Nature. 2020 May;581(7807):215-220
pubmed: 32225176
Protein Sci. 2018 Jan;27(1):14-25
pubmed: 28710774
Cell. 2019 Feb 21;176(5):1026-1039.e15
pubmed: 30712865
Sci Rep. 2018 Oct 24;8(1):15701
pubmed: 30356097

Auteurs

M Alejandra Tortorici (MA)

Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Institut Pasteur and CNRS UMR 3569, Unité de Virologie Structurale, Paris, France.

Martina Beltramello (M)

Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.

Florian A Lempp (FA)

Vir Biotechnology, San Francisco, CA 94158, USA.

Dora Pinto (D)

Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.

Ha V Dang (HV)

Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.

Laura E Rosen (LE)

Vir Biotechnology, San Francisco, CA 94158, USA.

Matthew McCallum (M)

Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.

John Bowen (J)

Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.

Andrea Minola (A)

Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.

Stefano Jaconi (S)

Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.

Fabrizia Zatta (F)

Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.

Anna De Marco (A)

Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.

Barbara Guarino (B)

Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.

Siro Bianchi (S)

Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.

Elvin J Lauron (EJ)

Vir Biotechnology, San Francisco, CA 94158, USA.

Heather Tucker (H)

Vir Biotechnology, San Francisco, CA 94158, USA.

Jiayi Zhou (J)

Vir Biotechnology, San Francisco, CA 94158, USA.

Alessia Peter (A)

Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.

Colin Havenar-Daughton (C)

Vir Biotechnology, San Francisco, CA 94158, USA.

Jason A Wojcechowskyj (JA)

Vir Biotechnology, San Francisco, CA 94158, USA.

James Brett Case (JB)

Departments of Medicine, Molecular Microbiology, Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.

Rita E Chen (RE)

Departments of Medicine, Molecular Microbiology, Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.

Hannah Kaiser (H)

Vir Biotechnology, San Francisco, CA 94158, USA.

Martin Montiel-Ruiz (M)

Vir Biotechnology, San Francisco, CA 94158, USA.

Marcel Meury (M)

Vir Biotechnology, San Francisco, CA 94158, USA.

Nadine Czudnochowski (N)

Vir Biotechnology, San Francisco, CA 94158, USA.

Roberto Spreafico (R)

Vir Biotechnology, San Francisco, CA 94158, USA.

Josh Dillen (J)

Vir Biotechnology, San Francisco, CA 94158, USA.

Cindy Ng (C)

Vir Biotechnology, San Francisco, CA 94158, USA.

Nicole Sprugasci (N)

Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.

Katja Culap (K)

Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.

Fabio Benigni (F)

Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.

Rana Abdelnabi (R)

Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Belgium.

Shi-Yan Caroline Foo (SC)

Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Belgium.

Michael A Schmid (MA)

Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.

Elisabetta Cameroni (E)

Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.

Agostino Riva (A)

III Division of Infectious Diseases, Luigi Sacco University Hospital, University of Milan, Italy.

Arianna Gabrieli (A)

III Division of Infectious Diseases, Luigi Sacco University Hospital, University of Milan, Italy.

Massimo Galli (M)

III Division of Infectious Diseases, Luigi Sacco University Hospital, University of Milan, Italy.

Matteo S Pizzuto (MS)

Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.

Johan Neyts (J)

Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Belgium.

Michael S Diamond (MS)

Departments of Medicine, Molecular Microbiology, Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.

Herbert W Virgin (HW)

Vir Biotechnology, San Francisco, CA 94158, USA.
Washington University School of Medicine, St. Louis, MO, USA.
UTSouthwestern Medical Center, Dallas, TX, USA.

Gyorgy Snell (G)

Vir Biotechnology, San Francisco, CA 94158, USA.

Davide Corti (D)

Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.

Katja Fink (K)

Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. dveesler@uw.edu katja.fink@alumni.ethz.ch.

David Veesler (D)

Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. dveesler@uw.edu katja.fink@alumni.ethz.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH